CCL24 Blockade with Nebokitug Modulates Inflammation and Fibrosis Signatures in Primary Sclerosing Cholangitis

Background and aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation, fibrosis, and innate immune dysregulation, with no approved therapies. Nebokitug (CM-101), a humanized monoclonal antibody targeting CCL24, demonstrated anti-inflammatory, anti-fibrotic, and anti-cholestatic activity in a Phase 2 clinical trial in patients with PSC. We performed comprehensive serum proteomic analyses to characterize the mechanistic effects of the CCL24 blockade following treatment with nebokitug.